Cerulea Clinical Trials has appointed senior pharmaceutical and biotechnology executive Dr Michelle Bradney as its new Chief Executive Officer.

Dr Bradney, who begins her role on 20 October, brings more than two decades of experience in medical affairs and clinical development across global pharmaceutical companies and ASX-listed biotechnology firms.

She joins Cerulea from OccuRx, where she served as Chief Operating Officer.

She has extensive ophthalmic clinical trials experience through senior roles at Allergan, where she led clinical monitoring operations.

Dr Bradney also holds governance roles in the life sciences sector, including as a board observer with Medicines Australia and a member of the Women on Boards Naomi Simson syndicate.

Cerulea Clinical Trials Chair Professor Keith Martin congratulated Dr Bradney on her appointment. He said her leadership would be instrumental in driving growth in the delivery of ophthalmic clinical trials at Cerulea.

“Michelle Bradney brings a wealth of experience in navigating complex regulatory environments and managing high-stakes clinical trial operations to Cerulea,” he said.

“I look forward to working with Michelle to expand the number of trials delivered, attract new industry-sponsored ophthalmic studies to Australia, and establish Cerulea as a global hub for ophthalmic clinical trials.”

Dr Bradney said she was thrilled to lead Cerulea at a critical time in its development.

“I’m thrilled to join Cerulea and build on the success of its clinical trial unit,” she said.

“Our goal is to attract new trials locally and internationally, giving people living with eye disease access to cutting-edge treatments and improving outcomes.”

Dr Bradney succeeds Dr Adele Hosseini, who has served as Interim CEO since May 2025.

“I thank Adele for her outstanding leadership as interim CEO, which has laid a strong foundation for the future growth and success of Cerulea” Professor Martin said.

About Cerulea Clinical Trials

Cerulea Clinical Trials is a specialist ophthalmic clinical trials centre based in Melbourne, Australia.

A fully owned not-for-profit subsidiary of the Centre for Eye Research Australia (CERA), Cerulea delivers Phase 1–4 clinical trials for industry and investigator-initiated studies.

The team specialises in advanced therapeutics, including gene and cell therapies, and partners with pharmaceutical and medtech companies worldwide to bring new treatments to market.